≥

Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting

December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…

1 week ago

Over half of the total leasing across the top 7 cities led by large-sized dealsTech occupiers continue to drive majority…

4 months ago